|
|
|
|
Science Sparks @ ACTREC
|
 2nd September 2024 |
Vol. No. 13 ; Issue No.646 |
|
|
Publications
|
|
1. Solanki S, Salunke B, Gangakhedkar G, Ambulkar R, Kuberkar D, Bhatt A (2024). Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy- A systematic review. European Journal of Surgical Oncology.
2. Dwivedi P, Kumar Jha A, Mithun S, Sawant V, Vajarkar V, Chauhan M, Choudhury S, Rangarajan V (2024). Dose estimation in patients from different protocols of 18F-FDG PET/CT studies and analysis of optimization strategies. Radiation Protection Dosimetry.
3.Salma NS, Vysakh R, Ranjith CP, Anjana PT, Gupta T, Laskar S (2024). Structural Quality Indicators in Radiation Oncology: Insights and Implications. Clinical Oncology.
|
|
|
|
|
Interesting Reads
|
|
Yang JC, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, Inoue T, Rodríguez-Cid J, Zhang L, Yang CT, de la Mora Jimenez E, Zhou J, Pérol M, Lee KH, Vicente D, Ichihara E, Riely GJ, Luo Y, Chirovsky D, Pietanza MC, Bhagwati N, Lu S (2024). Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. Journal of Clinical Oncology.
|
|
|
Video of the Week
|
|
| Hyperactive Ras Signaling in Developmental Disorders and Childhood Cancer |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2018, FDA approved larotrectinib, the first drug that targets tumors with NTRK gene fusions.
|
|
|
|
|
|
2024 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
